Atomico has led $56m series B round for Cambridge-allied rare disease therapy developer Healx, which also welcomed Intel Capital as a new shareholder.
Healx, a UK-based rare disease medication developer leveraging University of Cambridge technology, obtained $56m today in a series B round led by venture capital firm Atomico.
Intel Capital, a corporate venturing arm of semiconductor manufacturer Intel, also took part in the round, as did VC firms Global Brain, Btov Partners, Balderton Capital, Amadeus Capital Partners and private investor Jonathan Milner.
Founded in 2014, Healx is working on drug therapies for rare conditions using an artificial intelligence (AI)-equipped drug…
